509. A Comparison of Tocilizumab and Baricitinib for Hospitalized Patients with Severe COVID-19

BACKGROUND: Baricitinib (BARI) and tocilizumab (TOCI) are two FDA-approved immunomodulating agents for the treatment of COVID-19 patients with worsening respiratory status, but early studies suggest no differences in outcomes between the two therapies. METHODS: This is a single-center retrospective...

Descripción completa

Detalles Bibliográficos
Autores principales: Aytoda, Priyanka, Albrecht, Benjamin, Green, Sarah B, Harris, Gavin, Busch, Lindsay M, Sexton, Mary Elizabeth, Wiley, Zanthia, Rimawi, Ramzy H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678578/
http://dx.doi.org/10.1093/ofid/ofad500.578

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678578/
http://dx.doi.org/10.1093/ofid/ofad500.578

Ejemplares similares